ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,280.63
-0.02%
Dow Jones
42,352.75
0.81%
Gold vs US Dollar
2,646.025
-0.18%
Brent Oil
77.615
0.30%
Bitcoin
63,728.20
1.45%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Germany
  5. TG

  6. Ipsen SA (I7G) Share Price

I7G Ipsen SA

114.50
2.20 (1.96%)
04 Oct 2024 - Closed
Realtime Data
 Name  Symbol  Market  Type  ISIN  Description 
 Ipsen SA TG:I7G Tradegate (DE) Ordinary Share FR0010259150 
     Change  % Chg  Cur  Bid  Offer  High  Low  Open  Volume  Chg Time  RN  NRN 
   2.20 1.96 114.50 114.20 114.80 114.00 113.80 113.8 22 21:50:06   
 Type  Size  Price  Time  Units 
  2 114.00 15:29:58 EUR
 
Recent News
DateTimeSource
HeadlineMore I7G News
23/09/202412:13UKREGLe médicament Kayfanda® (odévixibat) d’Ipsen est approuvé dans l’Union européenne pour le prurit cholestatique lié au syndrome d’Alagille, une maladie hépatique rare
23/09/202412:13UKREGIpsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
20/09/202413:57UKREGLe médicament Iqirvo® (élafibranor) d’Ipsen est approuvé dans l’Union européenne comme premier nouveau traitement contre la cholangite biliaire primitive depuis près d’une décennie
20/09/202413:57UKREGIpsen’s Iqirvo® (elafibranor) approved in the European Union as first new treatment for primary biliary cholangitis in nearly a decade
16/09/202413:45UKREGFinal results from CABINET Phase III trial reinforce efficacy benefits of Cabometyx® in advanced neuroendocrine tumors
16/09/202413:45UKREGLes résultats finaux de l’essai de Phase III CABINET corroborent les bénéfices en termes d’efficacité de Cabometyx® dans les tumeurs neuroendocrines avancées
15/09/202413:45UKREGIpsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
Period
Draw mode
Data Downloads for I7G

Export historical price information open, high, low, close, volume (OHLCV) to Excel

Intraday price data (2 weeks, 1 minute bars)


Loading Follow Feed...

Latest Ipsen SA Articles